M&A In India May Lose Steam As Potential Sellers Raise Prices, Investment Bankers Say
This article was originally published in The Pink Sheet Daily
A rebound in the Indian stock market and two recent high-value takeovers sparked "irrational hope" in overvalued mid-size companies.
You may also be interested in...
MUMBAI - Weeks after the Paris-headquartered Sanofi-Aventis acquired Hyderabad-based Shantha Biotechnics to galvanize the French drug maker's preventative vaccines manufacturing, analysts are now predicting a deal between Britain's GlaxoSmithKline and Dr. Reddy's - India's second biggest pharmaceutical company as measured by sales
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year